Human CD47/B2M Double Knockout Cell Line-K562

CD47 encodes a transmembrane protein that is widely expressed on different cell types. By interacting with signal regulatory protein α (SIRPα) on macrophages, CD47 signals to inhibit phagocytosis, allowing the cell to evade immune surveillance. Cancer cells often exploit this mechanism to avoid destruction by the immune system. Overexpression of CD47 has been observed in many types of cancer, making it a promising therapeutic target. Antibodies that block the CD47-SIRPα interaction are currently being developed and tested in clinical trials, aiming to enhance the immune system's ability to target and eliminate cancer cells. Beta-2-microglobulin (B2M) is a component of the major histocompatibility complex (MHC) class I molecule, which is present in nearly all nucleated cells. B2M is associated with the heavy chain of MHC class I molecules and is essential for their stability and trafficking to the cell surface. Proper expression of MHC class I molecules is essential for immune recognition by cytotoxic T lymphocytes, which detect and eliminate cells that present abnormal antigens, such as those from viruses or transformed cancer cells. Mutations or alterations in the B2M gene can lead to loss of MHC class I expression, which can result in immune evasion. This phenomenon has been observed in various cancers, where loss of B2M expression is associated with poor prognosis and resistance to immune checkpoint blockade therapy.